|
| Home : Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of its Interleukin-31 Monoclonal Antibody for the Treatment of Atopic Dermatitis in Dogs |
|
Jul 29
2019 |
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of its Interleukin-31 Monoclonal Antibody for the Treatment of Atopic Dermatitis in Dogs |
|
SAN FRANCISCO, July 29, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot effectiveness study of KIND-016, a fully caninized, ... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/kindred-biosciences-announces-positive-results-from-pilot-field-effectiveness-study-of-its-interleukin-31-monoclonal-antibody-for-the-treatment-of-atopic-dermatitis-in-dogs-300892087.html |
| |
|
Related News
|
» Experts Analyze 4 Strategies to Monetize Your Data and Gain Competitive Edge
» Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance
|
|
|
